|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We conclude that the probe developed for RNA-ISH represents a viable, effective possible alternative to FISH and IHC for analysing HER2 status in primary breast tumours.
|
22763874 |
2012 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A systematic study of primary human breast tumor DNA demonstrated that three proto-oncogenes or regions of the genome (c-myc, int-2, and c-erbB2) are frequently amplified and that there is loss of heterozygosity (LOH) on chromosomes 1p(37%), 1q(20%), 3p(30%), 7(41%), 11p(20%), 13q(30%), 17p(49%), 17q(29%), and 18q(34%).
|
1540899 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
DNA aneuploidy and p53 or c-erbB-2 expression were simultaneously measured in 29 breast tumours by two-colour flow cytometry.
|
1360329 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
IMPLICATIONS: This study demonstrates these functional fluorescent probes' ability to report metabolic adaptations during primary tumor growth, regression, residual disease, and regrowth in Her2 breast tumors.
|
30902832 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These results all indicate that SPIONs-Cy-PEG-scFv are relevant tumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2 overexpressing breast tumor.
|
29466990 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.
|
1349163 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Despite the development of multiple targeted therapies for luminal and HER2+ breast tumors, TNBC lacks specific therapeutic approaches, thus they are treated mainly with radio- and chemotherapy.
|
30234015 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
|
18086299 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Over-expression of ERBB2, a member of the family of transmembrane receptor tyrosine kinases, occurs in 15-30% of primary breast tumors and is associated with poor prognosis and chemoresistance to a variety of anticancer drugs.
|
16685446 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
|
27788409 |
2016 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We assessed antitumor effects of squalamine either alone or with trastuzumab in nude mice bearing breast tumor xenografts without (MCF-7) or with HER2-overexpression (MCF-7/HER-2).
|
30771431 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
The clear relationship between HER-2/neu status and COX-2 expression in human breast tumors suggests that this mechanism is likely to be operative in vivo.
|
11901151 |
2002 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neu-overexpressing human breast tumor samples.
|
9380403 |
1997 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth receptor 2 (HER2) overexpressing breast tumors are known to be highly aggressive and metastatic.
|
30409762 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These three genes, c-myc, int-2/FGF3 (a marker for the 11q13 amplicon), and c-erbB-2/neu, were amplified in 37%, 14%, and 10% of breast tumors studied, respectively.
|
7892157 |
1994 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
For HR-/HER2+ breast tumor patients, the 3-year LRR rate was still lower for the cohort with trastuzumab (4.7% vs 8.6%).
|
27512838 |
2016 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
|
20197467 |
2010 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
ERBB2 is frequently amplified in breast tumours as part of a wide region of amplification on chromosome 17q21.
|
17117180 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples.
|
8105677 |
1993 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
FOXO1A may therefore serve as a target for HER2-overexpressing breast tumors.
|
20551062 |
2010 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Since HER2 is associated with tumors of an epithelial region and most of the breast tumors originate in epithelial tissue, it is crucial to develop an approach to segment different tissue structures.
|
31163391 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
ER, PR, and HER2 were determined by IHC in the primary breast tumor and the cell blocks of the pleural fluid with metastatic carcinoma.
|
27666130 |
2016 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
|
10897039 |
2000 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Studies evaluating the relationship of HER-2/neu breast tumor status and response to adjuvant endocrine therapy have reached conflicting conclusions about resistance of HER-2/neu-positive tumors to this treatment.
|
12560434 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
|
19896266 |
2010 |